Study S003315

A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

ClinicalTrials.gov record

Registration

Registration: NCT05848440
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 48
Start: 2023-05-02
Primary completion: 2023-11-13
Lead sponsor: AstraZeneca
Conditions: Non-alcoholic Steatohepatitis
Interventions: DRUG:AZD9550; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2022-003308-34

Registered primary outcomes

Adverse Events (AEs) and Serious Adverse Events (SAEs) [Throughout the study (up to 6 months)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.